Here are three notes:
1. Needham & Company also raised CONMED’s price target to $52.
2. Needham & Company analyst Mike Matson noted that the company’s new management, sales incentive changes, sales force hires and new products will help “drive revenue growth into the mid-single digits or better over the next two years” and he expects this to “drive EBITDA and multiple expansion.”
3. CONMED shares closed at $46.06 on May 1.
More articles on devices:
Anika Therapeutics’ total revenue up 44% to $22.3M — 5 things to know
Zimmer Biomet, NuVasive, Wenzel Spine & more: 21 key notes
Stryker to launch Tritanium Posterior Lumbar Cage: 4 takeaways
